Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Clinical diagnosis of non-radicular moderate-to-severe CLBP for ≥3 months (prior to screening visit)~2. Clinical diagnosis of OA in at least 1 hip or knee joint based on the American College of Rheumatology Criteria with radiographic evidence of OA (K-L ≥2) at screening~3. History of inadequate relief of CLBP from non-pharmacologic therapy~4. Willing to undergo joint replacement (JR) surgery, if necessary~5. History of regular analgesic medication use~6. History of inadequate pain relief or intolerance to analgesics used for chronic LBP~Key Exclusion Criteria:~1. Patient is not a candidate for MRI~2. History of major trauma or back surgery in the past 6 months prior to the screening visit~3. History or presence of pyriformis syndrome~4. Evidence on baseline lumbar spine magnetic resonance imaging of potentially confounding conditions~5. History or evidence on joint imaging of conditions that may confound joint safety evaluation~6. Evidence or symptoms consistent with autonomic dysfunction (e.g., orthostatic hypotension and/or autonomic symptoms) as defined in the protocol~7. Recent use of longer acting pain medications~8. Other medical conditions that may interfere with participation or accurate assessments during the trial~Note: Other protocol defined Inclusion/ Exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fasinumab (Type: EXPERIMENTAL): Subcutaneous (SC) every 4 weeks (Q4W)
- Placebo (Type: EXPERIMENTAL): SC every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).